BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 09, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

642444: Phase III started

GSK and Theravance began a pair of 6-month, double-blind, placebo-controlled Phase III trials in a total of 2,200 patients to evaluate 25 µg inhaled 642444 as monotherapy or in combination with 50, 100 or 200 µg inhaled fluticasone furoate (...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >